Nebulized Ensifentrine Significantly Improves Lung Function, COPD Symptoms
The ENHANCE-1 trial evaluated nebulized ensifentrine as monotherapy or as an add-on to a LAMA or a LABA in patients with moderate to severe COPD.
The ENHANCE-1 trial evaluated nebulized ensifentrine as monotherapy or as an add-on to a LAMA or a LABA in patients with moderate to severe COPD.
How does a delay in initiating triple therapy affect patients with COPD with a history of several moderate COPD exacerbations during a 1-year period?
Researchers assessed the effect of COPD severity on mortality and other outcomes of coronary artery bypass grafting.
How does cannabis affect COPD? To determine this, researchers assessed the risk for acute exacerbations of COPD in those who used cannabis vs those who did not.
Post hoc analysis of a real-world COPD trial assessed the effect of triple therapy in reducing exacerbations in patients with higher vs lower eosinophil levels.
In patients with COPD and asthma who are hospitalized for COVID-19, how does pre-hospitalization ICS use affect the clinical course of COVID-19?
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
Should patients with asthma or COPD have their inhaler regimens switched for nonclinical reasons? A systematic review examined real world evidence on this subject.
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?